Detection of BCR-ABL T315i Mutation in Imatinib Resistant Chronic Myeloid Leukemia Patients
- Author:
MARDZIAH M
1
Author Information
1. Department of Pathology
- Collective Name:MARDZIAH M; SALWATI S1; AZLIN I; HAFIZA A; NOOR FARISAH AR; NORAESAH M; TUMIAN NR; WONG CL; AZMA RZ
- Publication Type:Journal Article
- Keywords:
BCR ABL;
chronic myeloid leukemia;
T315I mutation
- From:Medicine and Health
2019;14(1):145-156
- CountryMalaysia
- Language:English
-
Abstract:
Chronic myeloid leukemia (CML) patients who have BCR-ABL T315I mutation,
usually present in the advance phase of the disease with overall survival (OS) shorter
than those without the mutation. This study aimed to determine the prevalence
of T315I mutation amongst imatinib mesylate (IM) resistant CML patients and to
compare the OS between T315I-mutated and non-T315I-mutated patients. Sixty
consecutive CML patients who were treated with IM for at least 18 months and
their treatment responses, were recorded. The mutation analysis was done using
allele-specific oligonucleotide reverse transcriptase-polymerase chain reaction
(RT-PCR) assay followed by direct sequencing technique. Forty-two patients (70%)
were found to have IM-resistance. Five out of 42 patients had detectable T315I
mutation. Median OS of IM-resistant T315I-mutated patients was 96 months
(95% CI:54-138) compared to 84 months (95% CI:48-120) in non T315I-mutated
patients, although this was found to be statistically insignificant (p = 0.43). The
present study showed a higher prevalence of T315I mutation as compared to a few
local studies. Median OS of T315I-mutated patients were observed to be longer
than non-T315-mutated patients. Further studies encompassing larger cohort of
patients are required to confirm this finding
- Full text:12.2019my0113.pdf
